By Dominic Chopping
--KKR is nearing a deal to buy E45 maker Karo Healthcare in a buyout that values the healthcare company at about 2.6 billion euros ($2.85 billion), Financial Times reports, citing unnamed sources.
--The U.S. private equity group bested a rival bid from PAI Partners to clinch the company behind over-the-counter medicines such as athlete's foot treatment Lamisil and moisturizer E45, paying 2.65 billion euros including debt, the people said, according to FT.
--Karo's current owner, EQT, struck a deal to take the business private in 2022, valuing it at about 1.4 billion euros. EQT first became a majority owner of Karo in 2019 when it was still a publicly-listed business.
-Karo, EQT and PAI declined to comment while KKR did not immediately respond to a request for comment, FT says.
Full story: https://tinyurl.com/4va2f8wt
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
April 09, 2025 01:47 ET (05:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.